

HeartWare HVAD for the Treatment of Patients with Advanced Heart Failure Ineligible for Cardiac Transplantation: Results of the ENDURANCE Destination Therapy Trial

FD Pagani¹, CA Milano², AJ Tatroles³, G Bhat³, MS Slaughter⁴, EJ Birks⁴, SW Boyce⁵, SS Najjar⁵, V Jeevanandam⁶, AS Anderson⁷, ID Gregoric⁸, RM Delgado⁹, K Leadley¹⁰, KD Aaronson¹, JG Rogers²

¹University of Michigan, Ann Arbor, MI, ²Duke University School of Medicine, Durham, NC, ³Advocate Christ Medical Center, Oak Lawn, IL, ⁴University of Louisville, Louisville, KY, ⁵MedStar Heart Institute, Washington, DC, ⁶University of Chicago Medicine, Chicago, IL, ⁷Northwestern Memorial Hospital, Chicago, IL, ⁸Surgical Associates of Texas, Houston, TX, ⁹Texas Heart Institute, Houston, TX, ¹⁰HeartWare, Framingham, MA,

ISHLT 35th Annual Meeting and Scientific Sessions
15-18th April, 2015, Nice, France

On behalf of all ENDURANCE investigators

- Anthony Rongione: Fairfax Inova Research Center
- Antone Tatoes: Advocate Christ Medical Center
- Bartley Griffith: University of Maryland
- Brian Bruckner: The Methodist Hospital
- Bruce Reid: Intermountain Medical Center
- Bryan Whitson, C.B. Sai-Sudhakar: Ohio State Univ. Med
- Carmelo Milano: Duke University Medical Center
- Charles Klodell: University of Florida, Gainesville
- Christiano Caldeira: Tampa General Hospital
- Christopher Salerno: St. Vincent Health CorVasc
- Craig Selzman: University of Utah
- Dan Meyer: UT Southwestern Medical Center (Dallas)
- Daniel Goldstein: Montefiore Medical Center
- Duc Thinh Pham: Tufts Medical Center
- David Vega: The Emory Clinic
- Francis Downey: St. Luke's Medical Center
- Francis Pagani: University of Michigan Hospital
- Gonzalo Gonzalez-Stawinski: Baylor University Medical
- Hari Mallidi, Igor Gregoric: Texas Heart Institute
- Howard Song: Oregon Health & Science University
- Jeffrey Miller, John O'Connell: St. Joseph Hospital Atlanta
- Johathan Philpott, Jeffrey Rich: Sentara Norfolk
- Joseph Cleveland: Univ. of Colorado Hospital-Leprino
- Mark Slaughter: Jewish Hospital
- Mark Zucker: Newark Beth Israel Medical Center
- Michael Acker: University of Pennsylvania
- Michael Bowdish, Mark Barr: Univ. of Southern California
- Nadir Moazami, Barry Cabuay: Minneapolis Heart Institute
- Nahush Mokadam: University of Washington Medical
- Nicholas Smedira: Cleveland Clinic Foundation
- Octavio Pajaro, Francisco Arabia: Mayo Clinic – Phoenix
- Patrick Parrino: Jack Ochsner Heart & Vascular Institute
- Phillip Oyer: Stanford University School of Medicine
- Ranjit John: University of Minnesota
- Robert Brewer: Henry Ford Hospital
- Robert Kormos: UPMC Presbyterian
- Salpy Pamboukian: University of Alabama - Birmingham
- Samer Najjar: Washington Hospital Center
- Sandra Chaparro, Raymond Hershberger: Univ. of Miami
- Scott Silvestry, Akinobu Itoh: Washington Univ./Barnes
- Soon Park, Lyle Joyce: Mayo Rochester-St. Mary's Hospital
- Thomas Wozniak: IU Health Methodist Hospital
- Travis Abicht, Ed McGee: Northwestern Memorial
- Valluvan Jeevanandam: University of Chicago
- Walter Dembitsky: Sharp Memorial
- Walter Pae: Milton S. Hershey Medical Center
- Yoshifumi Naka: NY Presbyterian-Columbia University

Relevant Financial Relationship Disclosure Statement




Investigational use of the


HeartWare[®] Ventricular Assist Device will be discussed.

FD Pagani: HeartWare research contract managed by the
University of Michigan.

Study Timelines



2008 2009 2010 2011 2012 2013 2014 2015



ENDURANCE Trial Design

A prospective and randomized trial to compare the safety and effectiveness of the HeartWare® HVAD System to a FDA-approved LVAD in patients with end-stage heart failure who do not qualify for heart transplantation.

Primary endpoint:


- Survival at two years free from disabling stroke (Modified Rankin Score ≥ 4 at 24-weeks post-stroke), and alive on the originally implanted device, or transplanted or explanted due to patient recovery

Secondary endpoints:

- Adverse events per INTERMACS definition (version 2.3)
- KCCQ and EuroQol EQ-5D Health Status
- NYHA functional class and 6-minute walk distance

ENDURANCE Study Devices

Treatment Device:



- Continuous flow centrifugal HVAD[®] Pump
- Pericardial placement
- FDA approved for BTT in 2012


Control Device:



- Continuous flow axial pump
- Sub-diaphragmatic placement
- FDA approved for BTT in 2008, DT in 2010

ENDURANCE Trial Design

Patients randomized from 04 August 2010 through 08 May 2012




*Crossovers: HVAD to control (N=4); control to HVAD (N=3)

Patient Characteristics and Demographics

Baseline Characteristics	HVAD (n=297)	Control (n=148)	P value
Age (years)	63.9	66.2	0.04
Gender: Male	76.4%	82.4%	0.18
Female	23.6%	17.6%	
Height (cm)	173.8	175.5	0.07
Body Surface Area (m ²)	2.0	2.0	0.62
INTERMACS Profile			0.85
1	3.4%	3.4%	
2	29.0%	31.1%	
3	40.4%	40.5%	
4	19.9%	18.2%	
5	4.0%	3.4%	
6	1.3%	0.0%	
7	2.0%	3.4%	
Ischemic Etiology of Heart Failure	57.9%	60.1%	0.68
Smoker	68.0%	62.2%	0.24
Stroke/TIA	19.2%	16.2%	0.51
Arrhythmia	78.1%	83.1%	0.26
Severe Tricuspid Insufficiency	11.8%	5.4%	0.04
Inotropes (pre-implant)	71.3%	71.1%	>0.99
Hypertension requiring medication	65.3%	70.9%	0.24

Non-inferiority Margins


Zone of Non-Inferiority
Pre-specified Margin = 15%



● — Upper 1-sided 95% Confidence Intervals
P values provided for example only

Primary Endpoint - Achieved


Survival at two years free from disabling stroke (MRS ≥ 4 at 24-weeks post-stroke), and alive on the originally implanted device, or transplanted or explanted due to patient recovery



	Days 0	365	730	1095
HVAD	297	210	156	33
Control	148	106	80	19

Primary Endpoint Non-inferiority Margins

Zone of Non-Inferiority
Pre-specified Margin = 15%



Non-Sintered



Sintered




● Upper 1-sided 95% Confidence Intervals

Sintered HVAD Pump = currently available pump

Primary Endpoint - Sintered HVAD vs. Control

Survival at two years free from disabling stroke (MRS ≥ 4 at 24-weeks post-stroke), and alive on the originally implanted device, or transplanted or explanted due to patient recovery



Sintered HVAD Pump = currently available pump

Binary Summary of Primary Efficacy Endpoint

Stroke Free Survival at 2 years	HeartWare (n=297)	Control (n=148)	<i>P</i> value
Success	164 (55.2%)	85 (57.4%)	0.69
Failure	133 (44.8%)	63 (42.6%)	0.69


Reasons for Failure			
Patient dies	103 (34.7%)	39 (26.4%)	0.08
Device malfunction, failure requiring exchange, urgent transplant, explant	26 (8.8%)	24 (16.2%)	0.025
Subject has disabling stroke (MRS \geq 4 at 24 weeks)	3 (1.0%)	0 (0.0%)	0.55
Imputed failure*	1 (0.3%)	0 (0.0%)	>0.99

* Patient experienced a stroke prior to their 2 year endpoint, and died beyond the 2 year endpoint, but before the 24 week MRS assessment.

Note: ENDURANCE defined each component hierarchically – e.g., if a patient has a disabling stroke and dies, they are counted as a death.

Kaplan-Meier Survival


Overall HVAD Compared to Control



	Days 0	Days 365	Days 730
HVAD	296	212	158
Control	149	108	86

Kaplan-Meier Survival

Sintered HVAD Compared to Control





HVAD	200	146	108
Control	149	108	86

Sintered HVAD Pump = currently available pump

NYHA Classification and 6 Minute Walk

Sustained improvements in patients' NYHA Classification*





Sustained and significant increase in total distance walked in both cohorts.*

*P=NS for all HVAD vs. Control comparisons

EQ-5D VAS and Overall KCCQ

Statistically significant improvements compared to baseline in EuroQol-5D Visual Analog Scores in both cohorts*



Sustained and significant improvements in Kansas City Cardiomyopathy Questionnaire overall summary scores in both cohorts*

*P=NS for all HVAD vs. Control comparisons


Overall CEC Adjudicated Adverse Events

INTERMACS defined events through 2 years

Adverse Event	HVAD (n=296)			Control (n=149)			P value
	No. of Patients	No. of events	EPPY (410.02PY)	No. of Patients	No. of events	EPPY (203.89PY)	
Bleeding	176 (59.5%)	400	0.98	90 (60.4%)	196	0.96	0.92
GI Bleed	103 (34.8%)	225	0.55	51 (34.2%)	90	0.44	0.92
Cardiac Arrhythmia	111 (37.5%)	175	0.43	61 (40.9%)	82	0.40	0.54
Infection	201 (67.9%)	452	1.10	92 (61.7%)	182	0.89	0.21
Driveline Infection	56 (18.9%)	72	0.18	21 (14.1%)	25	0.12	0.23
Stroke	85 (28.7%)	110	0.27	18 (12.1%)	19	0.09	<0.001
Ischemic CVA	50 (16.9%)	65	0.16	13 (8.7%)	13	0.06	0.021
Hemorrhagic CVA	42 (14.2%)	45	0.11	6 (4.0%)	6	0.03	0.001
TIA	24 (8.1%)	27	0.07	7 (4.7%)	7	0.03	0.24
Renal Dysfunction	43 (14.5%)	54	0.13	19 (12.8%)	22	0.11	0.67
Right Heart Failure*	110 (37.2%)	129	0.31	39 (26.2%)	45	0.22	0.025*
Pump Exchange	23 (7.8%)	27	0.06	20 (13.4%)	23	0.10	0.06


* There was no statistical difference in the rate of RHF in the sintered cohort vs . Control.

Pump Thrombosis (2 years)




Sintering reduced the overall rate of any suspected pump thrombus, and both overall thrombus rates and exchanges for thrombus were less frequent in patients with the currently available HVAD pump compared to control.

HVAD Thrombus Risk Factor Multivariable Analysis




- ✓ Statistically significantly more HVAD patients (7.3%, 0.07 EPPY) had a sub-therapeutic INR <2.0 compared to control patients (2.2%, 0.02 EPPY), $P=0.04$.

ICVA Risk Factor Multivariable Analysis (HVAD)



- ✓ Statistically significantly more HVAD patients (7.3%, 0.07 EPPY) had a sub-therapeutic INR <2.0 compared to control patients (2.2%, 0.02 EPPY), $P=0.04$.


HCVA Risk Factor Multivariable Analysis (HVAD)



Influence of Blood Pressure on Stroke (HVAD)

■ HVAD (MAP > 90 mmHg = 2+)

■ HVAD (MAP > 90 mmHg = 0 or 1)



- ✓ BP management is associated with improved neurological outcomes
- ✓ Blood pressure management was not mandated in ENDURANCE

Limitations

- Randomization was not stratified by site
- Changes to the study device and implant tools introduced mid-study may have impacted adverse events and/or outcomes
- Blood pressure management was not mandated in the protocol and varied among sites during follow-up
- Treatment arm had a higher rate of sub-therapeutic anticoagulation during follow-up

Summary

- Primary Endpoint achieved
- Patients had significant and sustained improvements in functional and quality of life measures
- Device malfunctions leading to exchange or urgent transplant were more frequent in the control group, whereas strokes occurred more frequently in the HVAD group
- Device and design improvements, including sintering of the inflow cannula, resulted in a reduction in pump thrombosis
- Elevated MAP was the strongest predictor of stroke by multivariable analysis. HVAD patients with well-managed blood pressure had fewer strokes

Conclusion

- There was **no difference between HVAD and control** in survival at two years free from disabling stroke (Modified Rankin Score ≥ 4 at 24-weeks post-stroke), and alive on the originally implanted device, or transplanted or explanted due to patient recovery

Future Directions

- Blood pressure management appears to reduce neurologic events and is being studied in the ongoing ENDURANCE Supplemental Trial

Acknowledgements

- ENDURANCE Investigators
- Clinical site coordinators
- Patients and families